Global Initiative for Psychedelic Science Economics

The Global Initiative for Psychedelic Science Economics (GIPSE) is a network of health economists dedicated to achieving the potential of psychedelic therapies for high-priority mental health conditions. 


Through the application of policy-relevant economic analyses, GIPSE seeks to enhance clinical outcomes, increase the efficiency of service delivery, and increase access to these promising therapies for everyone who can benefit. Some of their current projects include:

  • Modelling the cost-effectiveness of psilocybin-assisted psychotherapy to treat major depressive disorders in collaboration with the Usona Institute.
  • Evaluating the cost-effectiveness of MDMA-assisted therapy for people with chronic PTSD in collaboration with MAPS.
  • In collaboration with Johns Hopkins, evaluating the cost-effectiveness of psilocybin-assisted therapy for smoking cessation.
  • Modelling the short and long-term epidemiological, economic, and budgetary impacts of scaled-up access to psychedelic therapies at the state and national levels.

Based at UC Berkely, the team include Elliot Marseille, Stefano Bertozzi and Jim Khan.

Company Information

Global Initiative for Psychedelic Science Economics Website

January, 1970


Research Institute

Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships


HQ / Office UC Berkeley, Berkeley, CA, USA